KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

Entries with tag cell .

The Cell And Gene Therapy Catapult and University of Aberdeen Launch Islexa to Develop Novel Diabetes Technology

The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, announce the creation of Islexa, a new company developing a novel technology to produce laboratory grown islets, the organoids responsible for insulin production.  The technology could bring the option of an islet transplant to thousands more patients with type I diabetes. Currently in the UK, only 30-50...
Read More About The Cell And Gene Therapy Catapult and University of Aberdeen Launch Islexa to Develop Novel Diabetes Technology »

Funding Opportunities for SMEs in the Healthcare Sector: Webinar

    Funding Opportunities for SMEs in the Healthcare Sector - Webinar T he Cell and Gene Therapy Catapult, the Knowledge Transfer Network and H2020 National Contact Points will deliver a webinar on 30 June 2016 to highlight the forthcoming opportunities in Horizon 2020 Healthcare...
Read More About Funding Opportunities for SMEs in the Healthcare Sector: Webinar »

New Collaboration Opportunities In Regenerative Medicine

New Collaboration Opportunities in Regenerative Medicine and Addressing Challenges to Clinical Adoption of Cell and Gene Therapies New Hunts House Guy’s campus King’s College London London SE1 1UL 14 th June 2016 The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event...
Read More About New Collaboration Opportunities In Regenerative Medicine »

New company created to develop novel technology to treat diabetes

UK technology has potential to bring islet transplant therapy to thousands of patients with type 1 diabetes The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, today announce the creation of Islexa, a new company developing a novel technology to produce laboratory grown islets, the organoids responsible for insulin production. The technology could bring the...
Read More About New company created to develop novel technology to treat diabetes »

Oxstem closes record £16.9M fundraising round to design Stem Cell drugs to treat age-related disease

One of the most ambitious Oxford spinouts to date is on route to becoming a powerhouse in age-related regenerative medicine, developing drugs which can treat cancer, neurodegenerative diseases, heart failure, macular degeneration and other major age-related conditions. OxStem has raised a record £16.9m, and established strategic partnerships with world class biotechnology companies and...
Read More About Oxstem closes record £16.9M fundraising round to design Stem Cell drugs to treat age-related disease »

Oxford Biomedica updates on LentiVector

Oxford BioMedica plc, a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term four-year sustained and, in one of the studies, dose-dependent gene expression with the Company’s LentiVector® delivery platform. On 5 May 2016, Professor Stéphane Palfi presented a poster on OXB-101, a gene...
Read More About Oxford Biomedica updates on LentiVector »

Cellular Reprogramming and Culture of hiPSCs: a practical training course and UK Stem Cell Bank workshop on gene-editing

Cellular Reprogramming and Culture of hiPSCs: a practical training course and UK Stem Cell Bank workshop on gene-editing  23rd to 26th May 2016. This event brings together three successful training and workshop activities in stem cell technology:  Harvard Stem Cell Institute/UK Stem Cell Bank reprogramming training course (23rd May), EBiSC practical training course in iPSC...
Read More About Cellular Reprogramming and Culture of hiPSCs: a practical training course and UK Stem Cell Bank workshop on gene-editing »

Downstream Processing: From Cell to Column, Integrated Solutions for Rapid Bioprocessing of Biologics

Downstream Processing: From Cell to Column, Integrated Solutions for Rapid Bioprocessing of Biologics  When: November 2016, dates to be confirmed Where: Biochemical Engineering, University College London This course focuses on the biological product recovery stage and, through a series of lectures, case studies and pilot plant practical sessions, will enable you to: ...
Read More About Downstream Processing: From Cell to Column, Integrated Solutions for Rapid Bioprocessing of Biologics »

Minister joins ReNeuron Board on tour of their new premises

Economy Minister Edwina Hart joined the ReNeuron Board this week on a tour of their new premises at the Welsh Government’s state-of-the-art Advanced Therapy Medical Productions manufacturing facility at Pencoed. ReNeuron plc, the leading clinical stage stem cell business, has now relocated its operations from Guilford, in a move that was supported by the Wales Life Science Investment...
Read More About Minister joins ReNeuron Board on tour of their new premises »

Hands on Stem Cell Training Course: Human Pluripotent Stem Cells in Culture

Hands on Stem Cell Training Course: Human Pluripotent Stem Cells in Culture When: 25-27 April 2016 Where: Biochemical Engineering, University College London This is a 3-day hands-on, basic cell culture training course focusing on induced pluripotent stem cells (iPSC) and human embryonic stem cells (hESC).  The course is designed for life science and engineering...
Read More About Hands on Stem Cell Training Course: Human Pluripotent Stem Cells in Culture »

GSK, Miltenyi Biotec form cell and gene therapy alliance

GSK and Miltenyi Biotec have formed a strategic collaboration seeking to optimise the manufacture and delivery of personalised gene therapies.   The UK drugs giant is currently building a cell and gene therapy R&D platform to underpin development of novel therapies in oncology and rare diseases, reflecting its belief in cell and gene therapy’s potential as an important...
Read More About GSK, Miltenyi Biotec form cell and gene therapy alliance »

NICE recommends new sickle cell treatment device that could save the NHS millions

NICE is recommending a new device for managing sickle cell disease which makes treatment easier and quicker for patients, and could save the NHS in England around £13 million each year. The  NICE medical technology guidance  supports the use of the Spectra Optia Apheresis System for automated red blood cell exchange in patients with sickle cell disease who need regular...
Read More About NICE recommends new sickle cell treatment device that could save the NHS millions »

TrakCel selected for EU CAR-T Cell Therapy Project

TrakCel Ltd., a leading provider of Clinical supply chain orchestration technology for Cell, Gene and Immunotherapies, today announced its selection as a key partner in CARAT, an EU-funded project to support the development of CAR T cell therapies. The CARAT (Chimeric Antigen Receptors (CARs) for Advanced Therapies) project aims to integrate innovative cell manufacturing tools and...
Read More About TrakCel selected for EU CAR-T Cell Therapy Project »

Biotherapeutics device attracts $7m investment

A Cambridge life sciences company that has developed a revolutionary system for single-cell analysis in the biopharmaceutical market, with support from Innovate UK, has secured private investment totalling $7 million. Sphere Fluidics  Ltd’s Cyto-Mine® device promises to transform the discovery and development of biotherapeutics for treatment of cancer and inflammatory diseases and...
Read More About Biotherapeutics device attracts $7m investment »

Cell Therapy Catapult is now the Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, announces the official change of its name to the Cell and Gene Therapy Catapult. The new name more accurately reflects the activities of the organisation, the boom in gene modified cell therapies, and...
Read More About Cell Therapy Catapult is now the Cell and Gene Therapy Catapult »

Current Funding Opportunities through EU SME Instrument in support of manufacturing for cell based products

The medical applications of cell technologies include diagnostics and biosensors; cell and gene therapy, tissue engineering, bio-artificial organs, haematology, immunotherapy, and vaccine and antibody production; predictive toxicology, synthetic biology, and modelling development and disease processes. However, the diversity, complexity and variability of living cells pose challenges for...
Read More About Current Funding Opportunities through EU SME Instrument in support of manufacturing for cell based products »

Roslin Cells announces the creation of two commercially focused subsidiaries

Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announce that it has established two subsidiary companies to accelerate the expansion of its commercial operations.  Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials.  Roslin Cell Sciences will focus on the...
Read More About Roslin Cells announces the creation of two commercially focused subsidiaries »

ReNeuron wins major UK grant to advance its exosome nanomedicine platform

ReNeuron Group plc, a leading UK-based stem cell therapy development company, announce that it has been awarded a £2.1 million grant from Innovate UK to further advance its emerging exosome nanomedicine platform. Read more here  
Read More About ReNeuron wins major UK grant to advance its exosome nanomedicine platform »

Synpromics and Cell Therapy Catapult collaborate to develop viral vector manufacturing platform

Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and...
Read More About Synpromics and Cell Therapy Catapult collaborate to develop viral vector manufacturing platform »

Advances in Cell & Tissue Culture: Call for Papers

Advances in Cell & Tissue Culture And the 8th Annual Quasi Vivo® User Group Meeting 30th May– 1 st June 2016 Hotel SB Plaza Europa, Barcelona, Spain ACTC  2016 is a forum for leading researchers to present their work  on in vitro cell culture and exchange ideas. It is a ‘Gordon  Style’ event encouraging everybody to contribute by  presenting a...
Read More About Advances in Cell & Tissue Culture: Call for Papers »

Cell and Gene Therapy Manufacturing: Getting it right from the start

This three day training course is offered by the  Cell Therapy Catapult ,  UCL Biochemical Engineering  and the  amc . It is designed for cell and gene therapy professionals, from both industry and academia, who need to understand the manufacturing challenges and are planning, or progressing, a therapy through the R&D translation phases and into routine clinical...
Read More About Cell and Gene Therapy Manufacturing: Getting it right from the start »

Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the release of their 2015 Annual Review. The link to the annual review can be found here:  https://ct.catapult.org.uk/annual-review The second review covers the 12 months from...
Read More About Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review »

Cell Therapy Catapult signs major development agreement with Asterias Biotherapeutics Inc

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of an agreement with Asterias Biotherapeutics Inc (NYSE MKT: AST). The agreement engages the Cell Therapy Catapult to advance development of a large scale manufacturing processes for...
Read More About Cell Therapy Catapult signs major development agreement with Asterias Biotherapeutics Inc »

Cell Therapy Catapult appoints main contractor for Manufacturing Centre

The Cell Therapy Catapult has appointed M+W Group to construct its £55 million large-scale GMP manufacturing centre in Stevenage, UK. M+W Group, whose UK headquarters are in Chippenham, Wiltshire, UK has been appointed following a comprehensive Official Journal of the European Union (OJEU) compliant tendering process. Planning permission was granted by Stevenage Borough Council on 18...
Read More About Cell Therapy Catapult appoints main contractor for Manufacturing Centre »

UK Cell Therapy GMP Manufacturing Capacity and Capability Increases

The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. Key findings include: 25% increase in the numbers of highly-skilled staff at cell therapy facilities Addition of 2 cell therapy manufacturing centres 16% growth in the...
Read More About UK Cell Therapy GMP Manufacturing Capacity and Capability Increases »
Showing 1 - 25 of 35 results.
Items per Page 25
of 2